Drug Profile
AEF 0118
Alternative Names: AEF0118Latest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Aelis Farma
- Class Antifibrotics
- Mechanism of Action Cannabinoid receptor CB1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Fibrosis; Metabolic disorders
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for research development in Metabolic-disorders in France
- 28 Jul 2019 No recent reports of development identified for research development in Fibrosis in France
- 14 Nov 2017 Early research in Metabolic disorders in France (Aelis Farma pipeline, November 2017)